The Ad26.COV2.S investigational vaccine is being developed to prevent or lessen the severity of COVID-19, the disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The Ad26.COV2.S investigational vaccine includes bits of genetic material copied from the spikes of the SARS-CoV-2 virus. The goal is for the body to be immunized against COVID-19. The investigational vaccine does not contain the actual virus and cannot cause COVID-19. The ENSEMBLE study aims to test Janssen’s investigational vaccine in many different populations across the globe.
Visit ClinicalTrials.gov - NCT04505722 for additional details about the Janssen COVID-19 vaccine clinical study.
The J&J/Janssen vaccine requires 1 dose to prevent COVID-19 disease, hospitalization, and death. Independent experts who reviewed the safety data have concluded that the vaccine is safe.
We need your help to keep learning and improving vaccines against COVID-19. We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to end this pandemic. To participate:
Content last reviewed on July 15, 2021